Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Top Cited Papers
- 1 March 2008
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 371 (9617) , 987-997
- https://doi.org/10.1016/s0140-6736(08)60453-5
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnnals of the Rheumatic Diseases, 2007
- Assessing remission in clinical practiceRheumatology, 2007
- Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled studyArthritis & Rheumatism, 2007
- Evolving concepts of rheumatoid arthritisNature, 2003
- Fatigue in cancer patients compared with fatigue in the general United States populationCancer, 2002
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988